Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
PLoS Biol ; 16(12): e2005907, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30592710

RESUMEN

Metastatic dissemination employs both the blood and lymphatic vascular systems. Solid tumors dynamically remodel and generate both vessel types during cancer progression. Lymphatic vessel invasion and cancer cells in the tumor-draining lymph nodes (LNs) are prognostic markers for breast cancer metastasis and patient outcome, and tumor-induced lymphangiogenesis likely influences metastasis. Deregulated tumor tissue fluid homeostasis and immune trafficking associated with tumor lymphangiogenesis may contribute to metastatic spreading; however, the precise functional characterization of lymphatic endothelial cells (LECs) in tumors is challenged by the lack of specific reagents to decipher their rate-limiting role in metastasis. Therefore, we generated novel transgenic mice (PDPN promoter-driven Cre recombinase transgene [PDPN-Cre] and PDPN promoter-driven thymidine kinase transgene [PDPN-tk]) that allow for the identification and genetically controlled depletion of proliferating podoplanin (Pdpn)-expressing LECs. We demonstrate that suppression of lymphangiogenesis is successfully achieved in lymphangioma lesions induced in the PDPN-tk mice. In multiple metastatic breast cancer mouse models, we identified distinct roles for LECs in primary and metastatic tumors. Our findings support the functional contribution of primary tumor lymphangiogenesis in controlling metastasis to axillary LNs and lung parenchyma. Reduced lymphatic vessel density enhanced primary tumor lymphedema and increased the frequency of intratumoral macrophages but was not associated with a significant impact on primary tumor growth despite a marked reduction in metastatic dissemination. Our findings identify the rate-limiting contribution of the breast tumor lymphatic vessels for lung metastasis.


Asunto(s)
Neoplasias de la Mama/metabolismo , Glicoproteínas de Membrana/fisiología , Animales , Neoplasias de la Mama/fisiopatología , Movimiento Celular , Células Endoteliales/patología , Células Endoteliales/fisiología , Femenino , Humanos , Ganglios Linfáticos/patología , Linfangiogénesis/genética , Linfangiogénesis/fisiología , Sistema Linfático/fisiología , Vasos Linfáticos/patología , Macrófagos , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , Metástasis de la Neoplasia/fisiopatología , Timidina Quinasa/genética
2.
J Biol Chem ; 287(24): 19775-85, 2012 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-22511779

RESUMEN

SV40 small t-antigen (ST) collaborates with SV40 large T-antigen (LT) and activated rasv12 to promote transformation in a variety of immortalized human cells. A number of oncogenes or the disruption of the general serine-threonine phosphatase protein phosphatase 2A (PP2A) can replace ST in this paradigm. However, the relationship between these oncogenes and PP2A activity is not clear. To address this, we queried the connectivity of these molecules in silico. We found that p27 was connected to each of those oncogenes that could substitute for ST. We further determined that p27 loss can substitute for the expression of ST during transformation of both rodent and human cells. Conversely, knock-in cells expressing the degradation-resistant S10A and T187A mutants of p27 were resistant to the transforming activities of ST. This suggests that p27 is an important target of the tumor-suppressive effects of PP2A and likely an important target of the multitude of cellular oncoproteins that emulate the transforming function of ST.


Asunto(s)
Antígenos Transformadores de Poliomavirus/metabolismo , Transformación Celular Neoplásica/metabolismo , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/metabolismo , Proteína Fosfatasa 2/metabolismo , Sustitución de Aminoácidos , Animales , Antígenos Transformadores de Poliomavirus/genética , Línea Celular , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Humanos , Ratones , Mutación Missense , Proteína Fosfatasa 2/genética , Proteolisis
3.
Blood ; 116(3): 312-3, 2010 Jul 22.
Artículo en Inglés | MEDLINE | ID: mdl-20651081
4.
Cell Rep ; 10(7): 1066-81, 2015 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-25704811

RESUMEN

Strategies to target angiogenesis include inhibition of the vessel-stabilizing properties of vascular pericytes. Pericyte depletion in early-stage non-hypoxic tumors suppressed nascent angiogenesis, tumor growth, and lung metastasis. In contrast, pericyte depletion in advanced-stage hypoxic tumors with pre-established vasculature resulted in enhanced intra-tumoral hypoxia, decreased tumor growth, and increased lung metastasis. Furthermore, depletion of pericytes in post-natal retinal blood vessels resulted in abnormal and leaky vasculature. Tumor transcriptome profiling and biological validation revealed that angiopoietin signaling is a key regulatory pathway associated with pericyte targeting. Indeed, pericyte targeting in established mouse tumors increased angiopoietin-2 (ANG2/Angpt2) expression. Depletion of pericytes, coupled with targeting of ANG2 signaling, restored vascular stability in multiple model systems and decreased tumor growth and metastasis. Importantly, ANGPT2 expression correlated with poor outcome in patients with breast cancer. These results emphasize the potential utility of therapeutic regimens that target pericytes and ANG2 signaling in metastatic breast cancer.


Asunto(s)
Angiopoyetina 2/metabolismo , Neoplasias de la Mama/patología , Neoplasias Pulmonares/secundario , Angiopoyetina 2/inmunología , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Antígenos/genética , Antígenos/metabolismo , Hipoxia de la Célula , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Transición Epitelial-Mesenquimal , Femenino , Mesilato de Imatinib/farmacología , Neoplasias Pulmonares/patología , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Neovascularización Patológica , Pericitos/citología , Pericitos/efectos de los fármacos , Pericitos/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Proteoglicanos/deficiencia , Proteoglicanos/genética , Proteoglicanos/metabolismo , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/deficiencia , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/genética , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/metabolismo , Retina/fisiología , Transducción de Señal/efectos de los fármacos
5.
Dis Model Mech ; 6(4): 942-51, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23580202

RESUMEN

The regenerative response to drug- and toxin-induced liver injury induces changes to the hepatic stroma, including the extracellular matrix. Although the extracellular matrix is known to undergo changes during the injury response, its impact on maintaining hepatocyte function and viability in this process remains largely unknown. We demonstrate that recovery from toxin-mediated injury is impaired in mice deficient in a key liver extracellular matrix molecule, type XVIII collagen, and results in rapid death. The type-XVIII-collagen-dependent response to liver injury is mediated by survival signals induced by α1ß1 integrin, integrin linked kinase and the Akt pathway, and mice deficient in either α1ß1 integrin or hepatocyte integrin linked kinase also succumb to toxic liver injury. These findings demonstrate that type XVIII collagen is an important functional component of the liver matrix microenvironment and is crucial for hepatocyte survival during injury and stress.


Asunto(s)
Colágeno Tipo XVIII/metabolismo , Hepatopatías/metabolismo , Hepatopatías/patología , Hígado/metabolismo , Hígado/patología , Animales , Tetracloruro de Carbono , Muerte Celular , Colágeno Tipo XVIII/genética , Matriz Extracelular/metabolismo , Regulación de la Expresión Génica , Hepatocitos/metabolismo , Hepatocitos/patología , Integrina alfa1beta1/metabolismo , Ratones , Unión Proteica , Transducción de Señal , Análisis de Supervivencia , Factor de Crecimiento Transformador beta/metabolismo
6.
Cancer Cell ; 21(1): 66-81, 2012 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-22264789

RESUMEN

The functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia, epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis.


Asunto(s)
Transición Epitelial-Mesenquimal , Metástasis de la Neoplasia , Pericitos/fisiología , Proteínas Proto-Oncogénicas c-met/fisiología , Animales , Antineoplásicos/farmacología , Benzamidas , Bencenosulfonatos/farmacología , Neoplasias de la Mama/patología , Hipoxia de la Célula , Línea Celular Tumoral , Crizotinib , Femenino , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/fisiología , Mesilato de Imatinib , Indoles/farmacología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Transgénicos , Niacinamida/análogos & derivados , Pericitos/patología , Compuestos de Fenilurea , Piperazinas/farmacología , Piperidinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas c-met/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-met/metabolismo , Pirazoles , Piridinas/farmacología , Pirimidinas/farmacología , Pirroles/farmacología , Transducción de Señal , Sorafenib , Sunitinib , Células Tumorales Cultivadas
7.
Matrix Biol ; 29(8): 645-56, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20727409

RESUMEN

The lymphatic system is important for body fluid balance as well as immunological surveillance. Due to the identification of new molecular markers during the last decade, there has been a recent dramatic increase in our knowledge on the molecular mechanisms involved in lymphatic vessel growth (lymphangiogenesis) and lymphatic function. Here we review data showing that although it is often overlooked, the extracellular matrix plays an important role in the generation of new lymphatic vessels as a response to physiological and pathological stimuli. Extracellular matrix-lymphatic interactions as well as biophysical characteristics of the stroma have consequences for tumor formation, growth and metastasis. During the recent years, anti-lymphangiogenesis has emerged as an additional therapeutic modality to the clinically applied anti-angiogenesis strategy. Oppositely, enhancement of lymphangiogenesis in situations of lymph accumulation is seen as a promising strategy to a set of conditions where few therapeutic avenues are available. Knowledge on the interaction between the extracellular matrix and the lymphatics may enhance our understanding of the underlying mechanisms and may ultimately lead to better therapies for conditions where reduced or increased lymphatic function is the therapeutic target.


Asunto(s)
Matriz Extracelular/fisiología , Linfangiogénesis/fisiología , Sistema Linfático/fisiología , Animales , Matriz Extracelular/patología , Humanos , Sistema Linfático/patología , Sistema Linfático/fisiopatología , Neoplasias/etiología , Neoplasias/metabolismo , Neoplasias/patología , Neoplasias/fisiopatología , Neoplasias/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA